Orphan Drugs: Market Environment Products and CompaniesEspicom Healthcare Intelligence - December 17, 2012 - 68 Pages - SKU: ESPI4934452 |
The combination of government incentives to develop drugs for rare diseases and the promise of commercial opportunity will continue to fuel the industry’s interest in orphan drugs; and provide hope to patients with debilitating conditions and high unmet medical needs. In addition, the fast track approval system allows companies to enter the market faster and more cost-effectively with the potential to extend indications.
Significant unmet clinical need
While orphan diseases are rare, patients with rare diseases are numerous. There are up to 7,000 identifiable rare diseases, affecting an estimated 622 million people around the world. There is a ... read the full abstract
Significant unmet clinical need
While orphan diseases are rare, patients with rare diseases are numerous. There are up to 7,000 identifiable rare diseases, affecting an estimated 622 million people around the world. There is a ... read the full abstract
Since 1998, MarketResearch.com has provided companies with the business intelligence and research they need to make informed decisions.
We provide information on products, trends, regions, demographics, industries and companies from our collection of over 700 research publishers and 400,000 research reports.
About Us
We provide information on products, trends, regions, demographics, industries and companies from our collection of over 700 research publishers and 400,000 research reports.
About Us
